share_log

Cullinan Oncology Analyst Ratings

Cullinan Oncology Analyst Ratings

库利南肿瘤分析师评级
Benzinga Analyst Ratings ·  2022/11/21 06:42
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/21/2022 61.16% BTIG → $20 Initiates Coverage On → Buy
05/13/2022 101.45% SVB Leerink $36 → $25 Maintains Outperform
03/18/2022 327.07% HC Wainwright & Co. $55 → $53 Maintains Buy
06/07/2021 246.49% Morgan Stanley $40 → $43 Maintains Overweight
06/04/2021 343.19% HC Wainwright & Co. $48 → $55 Maintains Buy
06/04/2021 335.13% SVB Leerink $48 → $54 Maintains Outperform
04/27/2021 — Morgan Stanley Upgrades Equal-Weight → Overweight
04/19/2021 222.32% Morgan Stanley $38 → $40 Maintains Equal-Weight
03/30/2021 286.78% HC Wainwright & Co. $47 → $48 Maintains Buy
02/02/2021 343.19% Evercore ISI Group → $55 Initiates Coverage On → Outperform
02/02/2021 319.02% SVB Leerink → $52 Initiates Coverage On → Outperform
02/02/2021 — Morgan Stanley Initiates Coverage On → Equal-Weight
02/01/2021 278.73% HC Wainwright & Co. → $47 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
11/21/2022 61.16% BTIG → $20 开始承保 →购买
05/13/2022 101.45% SVB Leerink $36 → $25 维护 跑赢大盘
03/18/2022 327.07% HC Wainwright公司 $55 → $53 维护 买
06/07/2021 246.49% 摩根士丹利 $40 → $43 维护 超重
06/04/2021 343.19% HC Wainwright公司 $48 → $55 维护 买
06/04/2021 335.13% SVB Leerink $48 → $54 维护 跑赢大盘
04/27/2021 — 摩根士丹利 升级 等重→超重
04/19/2021 222.32% 摩根士丹利 $38 → $40 维护 等重
03/30/2021 286.78% HC Wainwright公司 $47 → $48 维护 买
02/02/2021 343.19% Evercore ISI集团 → $55 开始承保 →跑赢大盘
02/02/2021 319.02% SVB Leerink → $52 开始承保 →跑赢大盘
02/02/2021 — 摩根士丹利 开始承保 →等重
02/01/2021 278.73% HC Wainwright公司 → $47 开始承保 →购买

What is the target price for Cullinan Oncology (CGEM)?

库利南肿瘤(CGEM)的目标价格是多少？

The latest price target for Cullinan Oncology (NASDAQ: CGEM) was reported by BTIG on November 21, 2022. The analyst firm set a price target for $20.00 expecting CGEM to rise to within 12 months (a possible 61.16% upside). 3 analyst firms have reported ratings in the last year.

库利南肿瘤学(纳斯达克：CGEM)的最新目标价是由BTIG于2022年11月21日报道的。这家分析公司将目标价定为20.00美元，预计CGEM将在12个月内上涨(可能上涨61.16%)。3家分析公司在过去一年公布了评级。

What is the most recent analyst rating for Cullinan Oncology (CGEM)?

库利南肿瘤学(CGEM)的最新分析师评级是多少？

The latest analyst rating for Cullinan Oncology (NASDAQ: CGEM) was provided by BTIG, and Cullinan Oncology initiated their buy rating.

纳斯达克(BTIG)提供了对库利南肿瘤学的最新分析师评级，库利南肿瘤学启动了他们的买入评级。

When is the next analyst rating going to be posted or updated for Cullinan Oncology (CGEM)?

库利南肿瘤学(CGEM)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cullinan Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cullinan Oncology was filed on November 21, 2022 so you should expect the next rating to be made available sometime around November 21, 2023.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与库利南肿瘤公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。库利南肿瘤学的上一次评级是在2022年11月21日提交的，所以你应该预计下一次评级将在2023年11月21日左右的某个时候提供。

Is the Analyst Rating Cullinan Oncology (CGEM) correct?

分析师对库利南肿瘤学(CGEM)的评级正确吗？

While ratings are subjective and will change, the latest Cullinan Oncology (CGEM) rating was a initiated with a price target of $0.00 to $20.00. The current price Cullinan Oncology (CGEM) is trading at is $12.41, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的库利南肿瘤学(CGEM)评级是以0.00美元至20.00美元的目标价启动的。库利南肿瘤公司(CGEM)目前的交易价格为12.41美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发